Introduction
Lymphomas are hematological malignancies, which are divided into non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). Non-Hodgkin lymphoma (NHL) is a lymphoma-derived malignancy that makes up about 90% of all malignant lymphoma [1] . According to its origin, NHL is classified into B-cell NHL and T-cell NHL. The most common types are follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL) [2, 3] . NHL mortality has increased in recent years and has become the seventh most frequently occurring cancer [4] . Although many therapies have emerged, for example the current combination of cyclophosphamide, doxorubicin,
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Molecular genetics of NHL in different subtypes
NHL commonly occurs along with molecular genetic abnormalities. Certain molecular genetic abnormalities in NHL are related to specific lymphoma subtypes, which are associated with prognosis or potential therapeutic targets. Different translocations and mutations can be characteristic of different subtypes of NHL. Currently, classification of NHL is based on morphology and immunophenotype. This article will give you a new insight into classification of NHL from specific genetic changes (Table 1) , which may be helpful with prediction of outcome and guidance of therapy.
Burkitt lymphoma
Burkitt lymphoma (BL) is characterized by overexpression of the oncogene MYC. This form results from translocation, combining the MYC locus at 8q24.21 with an immunoglobulin gene locus [22] . Although overexpression of MYC is driven by an immunoglobulin gene enhancer generally associated with BL, recurrent genetic abnormalities apart from MYC are reported. Abnormalities of chromosomes 1, 6, 7, 13, 17 and 22 are reported in pediatric BL [23] [24] . In studies of BL samples, cytogenetic abnormalities have been reported. About 25-33% of BL patients have gained through translocation in 1q, 11-18% have gained in 3q and 14-18% have lost in 17q [25, 26] . Meanwhile, 13q33.1-q34 and Xp22.33 are both lost.
cycle, metabolism, chromatin modification, protein modification and organelle organization [15] . In this reference, Deep sequencing of miRNA (miRNA -seq) was used to study expression and dysregulation of candidate novel and known miRNAs. According to this report, 25 miRNA appeared to be related to survival of DLBCL patients. Among these 25 miRNAs, when miR-28-5p, miR-214-5p, miR-339-3p and miR-5586-5p are upregulated, the survival of patients increases. However, other miRNAs, such as miR-324-5p and NOVELMOO203M, occurring with higher level of expression are associated with increased mortality [16] . In order to study the relationship between miRNA expression and patient overall survival (OS) and progression-free-survival (PFS), log-rank tests on X-tile-derived low and high expression patient groups were performed [15] . It is reported that 58 miRNAs are associated with OS and 45 miRNAs are related to PFS. For example, miR-330 [16] , miR-93, miR-148a, miR-151, miR-28 [17] , miR-155 [18] , miR-181a [18] etc. In view of the effect of miRNAs on cancer process, 15 miRNAs are identified as abundantly expressed in B-cells. One of these 15 miRNAs, miR-142, plays an important role in B-cell function [19] . Three of these 15 miRNAs, which are miR-3150b-3p, miR-6087, and miR-4491, are abundantly expressed in B-cells [20] . It is noteworthy that the miR-200 family, including miR-200a-3p, miR-200a-5p, miR-200b-3p, miR-200b-5p, miR-200c-3p and miR-200-5p are decreased significantly in expression in B-cells [21] . This data suggests that these miRNAs may participate in some specific function in B-cell lymphoma. These findings may provide us with a new understanding of NHL lymphoma biology and therapeutic schedule. 
Follicular lymphoma
Follicular lymphoma (FL) is an uncommon type of B-cell NHL. Most FL cases are characterized by t(14;18) translocation involving IGH and BCL2, which results in overexpression of BCL2 [24] . Generally, FL betides older adults and shows significant differences with younger patients in morphological, clinical and genetic features. Cases that occur in younger patients are characterized by mutation of TNFRSF14 at 1p36 in about 41% [36] .
T lymphoblastic lymphoma
T lymphoblastic lymphoma (T-LBL) is the second most common NHL. Another similar subtype of T-cell lymphoma is T-cell Acute Lymphoblastic Leukemia (T-ALL). As WHO classification showed, these two types of lymphoma are both named as T lymphoblastic leukaemia/ lymphoma [37] . However, T-LBL patients demonstrate poor outcomes for therapy or relapse when treated the same as T-ALL. Therefore, it is necessary to evaluate large cohorts to find more detailed genetic characterization compared with T-ALL (Table 2) . This article will list some examples detailing the different molecular genetics between T-LBL and T-ALL. About 56-69% abnormal karyotypes, with 3-5% hyperdiploid, 25-44% pseudodiploid and 22-25% hyperdiploid were shown in both T-LBL and T-ALL [38] .
Translocation of the T-cell receptor (TCR) loci exists in both T-LBL and T-ALL. Transformation of expression occurs when oncogenes are combined with TCR regulatory regions on chromosomes 7q34 [TRB (TCR ß)], 7q14 [TRG (TCR γ)], or 14q11 [TRD (TCR α) and TRD (TCR δ)] [39]
. A recent study shows that 2-15% of pediatric T-LBL patients also have translocation of 9q34. Many of the oncogenes associated with T-ALL, such as NOTCHI, ABL1, SET and NUP214 also exists in 9q34. Thus, it is reasonable that translocation involving 9q34 are more common in T-ALL than T-LBL [38] . The gene FBXW7 is closely related to NOTCHI mutation. Reduced FBXW7 function via mutation, leads to the up regulation of the oncogene NOTCHI and thereby increases its signaling [40] . Although collecting the genetic characteristics related to gene expression for T-LBL remains a daunting task, the addition of new and helpful sequencing technologies and group efforts will make it within our reach. This molecular genetic abnormality in BL has become a good guidance for classification of NHL. Taking 25 cases of BL for example, nineteen of atypical BL cases were classified as BL by the molecular classifier. Furthermore, some cases diagnosed as DLBCL in terms of pathology were classified correctly.
Diffuse large B-cell lymphoma
DLBCL is defined via characterization of morphology and immunophenotype. This type of NHL is closely associated with BCL6, BCL2 and MYC translocations. If any two of these genetic translocations are referred to as double-hit lymphoma, prognosis for adult patients will be poor [27] . Therefore, studying double-hit lymphoma cases may have an effect on treatment decisions. DLBCL is classified into activated B-cell-like (ABC) and germinal center B-cell-like (GCB) subtypes, which is mentioned above. When the DLBCL gene is sequenced, it is found that MYD88, KLHL14, CD79B, SIGLEC10 are commonly upregulated in the ABC subtype; GNA13, BCL2, EZH2 predominantly in the GCB subtype [28] . Another novel finding demonstrates that mutation of EZH2 and KMT2D (MLL2) in the GCB subtype may impact histone modifications and transcriptional regulation in DLBCL patients [29, 30] . Primary mediastinal large B-cell lymphoma (PMBL) that mainly arises in the anterior mediastinum is more common in adolescent and young adult female patients [24] . Currently, it is indicated that when genomic gains of 9p24 [JAK2, CD274 (PD-L1)] and PDCD1L (PD-L2)] and 2p15 (REL and BCL11A) are enhanced in PMBL, immune system and STAT3 will be activated [32] . As an uncommon lymphoma, PMBL is recognized distinctly from typical DLBCL, which is helpful with targeted therapies [33] .
B lymphoblastic lymphoma
The more common type of B lymphoblastic lymphoma is B acute lymphoblastic leukemia (B-ALL), with B lymphoblastic lymphoma (B-LBL) being much more rare. Limited data for B-LBL results in limited therapies. B-LBL is treated according to B-ALL protocols [34] . Thus, it is urgent to distinguish B-ALL from B-LBL via genomic. A study shows that a translocation t(2;8) (p12;q12) related to the site of the ICK locus, 2p12 has become the characteristic of B-LBL. However, further work with larger sample sizes should be done to characterize the
Summary and further study
This article has summarized some of the key molecular genetics of NHL from miRNAs (DLBCL for example) and other types of molecular genetics (BL, DLBCL, B-and T-LBL, FL for examples). Some of these molecular genetic abnormalities involved translocation and mutation. All of these phenomenon play crucial roles in the progression, pathogenesis and prognosis of cancer. Difference in roles of each molecular genetic component also provides for us more information about the classification of NHL and guidance for therapeutic decision-making. Overall, NHL is very common in oncology and constitutes a large percentage of all neoplasia. NHL molecular characterization is not comprehensive for all subtypes due to a lack of adequate sampling. In order to improve therapeutic effects and outcomes for any subtype of NHL, a large cooperation and effort must be made to collect and share information about cutting-edge genomic and genetic analyses.
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Genetic changes Significance
Absence of Bi-allelic TRG deletion (ABD) NOTCHI-activating mutation Implies early T cell maturational arrest NS Most common gene mutation FBXW7 mutation PTEN mutation KRAS and NRAS mutation LOH6q16
Decrease NOTCHI degradation Activates PI3K-SKT cascade NS Distinct from LOH6q14-15 in T-ALL; affects CASP8AP2 Deletion or LOH of chromosome 9p
Affects CDKN2A/CDKN2B loci, which encode multiple tumor suppressors T-LBL, T cell lymphoblastic lymphoma; LOH, loss of heterozygosity; NS, not significant
